Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial
Olivier Mir(Institut Gustave Roussy), Étienne Minvielle(École Polytechnique), A. Fourcade(Institut Gustave Roussy), Delphine Mathivon(Institut Gustave Roussy), David Malka(Université Paris Cité), Stéphane de Botton(Université Paris-Sud), Mario Di Palma(Institut Gustave Roussy), Marie Ferrua(Institut Gustave Roussy), David Planchard(Institut Gustave Roussy), Vanessa Puglisi(Institut Gustave Roussy), Éric Baudin(Institut Gustave Roussy), Patricia Pautier(Institut Gustave Roussy), Florian Scotté(University of Derby), Laurence Albigès(Institut Gustave Roussy), M. Guillet(Institut Gustave Roussy), Adeline Duflot-Boukobza(Institut Gustave Roussy), Suzette Delaloge, Sarah Dumont(Institut Gustave Roussy), Caroline Robert(Centre National de la Recherche Scientifique), May Abbas(Institut Gustave Roussy), François Lemare(Institut Gustave Roussy)
Cited by 138
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k